Interestingly, in a recent post hoc study, further analysis of plasma samples from this trial revealed that tirzepatide dose-dependently lowered triglyceride, apoC-III, and apoB levels over time and reduced the number of large triglyceride-rich lipoprotein particles and small low-density lipoprotein particles compared to dulaglutide and/or placebo [86]
May your protocols stay optimized, your metabolic health stay improving, and your research stay informed by evidence rather than hype.
[DOI] [Google Scholar] 137.Giagulli V.A., Carbone M.D., Ramunni M.I., Licchelli B., De Pergola G., Sabb C., Guastamacchia E., Triggiani V
Comprender estos plazos ayuda a establecer expectativas realistas y optimizar la adherencia al tratamiento